

10/509036

Figure 1




Figure 2




Figure 3

1 MDPAGGPRGVLPPCRVLVLLNPRGGKGKALQLFRSHVQPLLAAEAEISFTLMLTERRNHARELVSRSEELG 70
71 RWDALVVMGSGDGLMHEVVNGLMERPDWETAIQKPLCSLPAGSGNALAASLNHYAGYEQVTNEDLLTNCTL 140
141 LLCRRLLSPMNLLSLHTASGLRFLFSVLSLAWGFIADVDDLESEKYPRLGEMRFTLTGFLRLAALRTYRGRL 210
211 AYL PVGRVGSKTPASPPVVVQQGPVDAHLVPLEEPVPSHNTVVPDEDFVLVLLHSHLGSEMFAAPMGRC 280
281 AAGVMHLFYVRAGVSRAMLLRLFLAMEKGRHMEYECPLYVVPVVAFRLEPKDGKGMFAVDGELMVSEAV 350
351 QGVHPNYPWMVSGCPEPPPSWKPPQMPPEEPL 384

Figure 4




Figure 5

	<u>hSK^{S225A}</u>		<u>hSK^{WT}</u>		<u>hSK^{S220A}</u>		<u>hSK^{T222A}</u>	
PMA	-	+	-	+	-	+	-	+

Figure 6




Figure 7




Figure 7




Figure 8




Figure 9




Figure 10A

Figure 10A




Figure 10A




Figure 10A



Figure 10B




Figure 10C




Figure 11

Figure 11

Figure 11

Figure 11




Figure 12

antagonists directly targeting the catalytic activity

(eg. Drugs targeting ATP or Sphingosine binding sites)

ATP Sphingosine

antagonists targeting activation

hSK1

Protein kinase
(Erk2?)




Figure 13




Figure 14




Figure 15




Figure 16





Figure 17






Figure 18




Figure 18